Alterity Financial Statements From 2010 to 2025

Stocks . Australia . 
Stock . Alterity Therapeutics
ATH Stock   0.01  0.0005  5.56%   
Analyzing historical trends in various income statement and balance sheet accounts from Alterity Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alterity Therapeutics' valuation are summarized below:
Gross Profit
5.3 M
Profit Margin
(2.23)
Market Capitalization
92.4 M
Enterprise Value Revenue
164.749
Revenue
5.4 M
There are currently eighty-six fundamental signals for Alterity Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Alterity Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.

Alterity Therapeutics Total Revenue

5.71 Million

Check Alterity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alterity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.9 K, Other Operating Expenses of 11.3 M or Total Operating Expenses of 11.2 M, as well as many indicators such as . Alterity financial statements analysis is a perfect complement when working with Alterity Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Alterity Therapeutics Technical models . Check out the analysis of Alterity Therapeutics Correlation against competitors.
For more information on how to buy Alterity Stock please use our How to Invest in Alterity Therapeutics guide.

Alterity Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets48.3 M46 M27.2 M
Slightly volatile
Cash34.8 M33.2 M21 M
Slightly volatile
Cash And Short Term Investments42.7 M40.7 M22 M
Slightly volatile
Common Stock Total Equity194 M184.8 M141.5 M
Slightly volatile
Common Stock Shares Outstanding6.7 B6.4 B1.8 B
Slightly volatile
Liabilities And Stockholders Equity48.3 M46 M27.2 M
Slightly volatile
Total Liabilities2.6 M3.6 M3.1 M
Slightly volatile
Total Current Assets48.2 M45.9 M27.1 M
Slightly volatile
Common Stock276.1 M262.9 M163.4 M
Slightly volatile
Other Current Liabilities1.7 M2.8 M2.1 M
Slightly volatile
Total Current Liabilities2.8 M3.5 M3.1 M
Slightly volatile
Property Plant And Equipment Net108.5 K155.2 K99.9 K
Slightly volatile
Accounts Payable1 M538.3 K917.5 K
Slightly volatile
Non Current Assets Total147.4 K155.2 K972.4 K
Slightly volatile
Net Receivables2.7 M3.9 M3.7 M
Slightly volatile
Other Current Assets1.3 M1.3 M785.8 K
Slightly volatile
Property Plant And Equipment Gross203 K155.2 K234.8 K
Slightly volatile
Intangible Assets10 M10.3 M11.4 M
Slightly volatile
Non Current Liabilities Total68.4 K88.5 K34.1 K
Slightly volatile
Short Term Debt129.4 K133.8 K151.1 K
Pretty Stable
Short and Long Term Debt Total173 K155.5 K156.5 K
Slightly volatile
Other Liabilities15.1 K22.4 K11.9 K
Slightly volatile
Net Tangible Assets19.8 M20.5 M27.6 M
Slightly volatile
Capital Surpluse7.5 M8.4 M9.2 M
Slightly volatile
Property Plant Equipment324.7 K309.2 K122.3 K
Slightly volatile
Net Invested Capital25.5 M42.4 M23.5 M
Pretty Stable
Cash And Equivalents21 M40 M23.5 M
Slightly volatile
Net Working Capital25.4 M42.3 M23.4 M
Pretty Stable
Capital Stock224.5 M262.9 M181.6 M
Slightly volatile
Capital Lease Obligations136 K155.5 K73.8 K
Slightly volatile

Alterity Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses11.3 M20 M12.6 M
Slightly volatile
Total Revenue5.7 M5.4 M1.9 M
Slightly volatile
Research Development8.5 M14.4 M10.4 M
Slightly volatile
Depreciation And Amortization26.9 K28.3 K117.5 K
Slightly volatile
Selling General Administrative4.8 M5.5 M4 M
Slightly volatile
Selling And Marketing Expenses8.3 K8.7 K89.8 K
Slightly volatile
Interest Income584.2 K446.3 K1.7 M
Slightly volatile
Net Interest Income468.6 K446.3 K154.8 K
Slightly volatile
Reconciled Depreciation86.1 K139.7 K57.4 K
Slightly volatile

Alterity Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.4 M12.6 M18.9 M
Pretty Stable
Depreciation194 K139.7 K136.2 K
Pretty Stable
End Period Cash Flow18.6 M33.2 M20.3 M
Pretty Stable
Sale Purchase Of Stock44.7 M42.6 M15.4 M
Slightly volatile
Issuance Of Capital Stock44.7 M42.6 M17.3 M
Slightly volatile

Alterity Fundamental Market Drivers

About Alterity Therapeutics Financial Statements

Alterity Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Alterity Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Alterity Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Alterity Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14.4 K13.7 K
Total Revenue5.4 M5.7 M
Cost Of Revenue127.5 K133.9 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alterity Stock Analysis

When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY